SFA Therapeutics
PrivateLast Round
Series A
Mar 13, 2025
Est. Valuation
$250M
Total Funding Raised
$4.23M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
SFA Therapeutics operates in Healthcare & Life Sciences and is based in Jenkintown, Pennsylvania. Its latest recorded funding round was a VC Round in November 2023.
SFA Therapeutics is a clinical-stage biopharmaceutical company that develops oral, small-molecule therapeutics for autoimmune diseases, chronic inflammatory diseases, and cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SFA Therapeutics Comparables
Compare SFA Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Artax Biopharma | 83% | |
| Evommune | 78% | |
| Can Fite Biopharma Ltd ADR | 78% |
For institutional investors. Book with your work email.
SFA Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Mar 13, 2025 | ||||
| VC Round | Nov 9, 2023 | ||||
| Seed | Jun 20, 2022 | ||||
| Accelerator | Sep 2, 2021 | ||||
| Grant | Jun 24, 2020 | ||||
Seed | Jul 31, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
SFA Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| INP Capital | Seed |
| Benjamin Franklin Technology Partners | Seed, VC Round, Grant |
| Acequia Capital | Seed |
| Asymmetry Ventures | Seed, VC Round |
| Y Combinator | Accelerator |
| Montgomery County, Pennsylvania | Seed, VC Round, Grant |
| Boost VC | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 465% MoM.
- Apr 17, 2026
Monthly visitors increased 44% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 7, 2026
SFA Therapeutics, Inc. presents two head-to-head preclinical studies of its oral candidate SFA-002 at the American Academy of Dermatology (AAD) Annual Meeting in Florida in Mar '25.
- promotesAug 19, 2026
SFA Therapeutics, Inc. moves co-founder Dr. Ira C. Spector from CEO to Chief Strategy Officer effective immediately on Aug 19th '26, and he continues guiding development of its immunology and pancreatic cancer portfolio.
- hiresAug 19, 2026
SFA Therapeutics, Inc. appoints Chairman Shawn Patrick O'Brien as CEO effective immediately in Pennsylvania on Aug 19th '26, as the clinical-stage biopharmaceutical company advances its psoriasis and pancreatic cancer programs.
For institutional investors. Book with your work email.
SFA Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about SFA Therapeutics's valuation, stock price, and market status.
Is SFA Therapeutics a public or private company?
SFA Therapeutics is a private company.
What is the current stock price of SFA Therapeutics?
SFA Therapeutics is a private company, so its shares have no public market price. Caplight tracks SFA Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SFA Therapeutics worth (valuation)?
SFA Therapeutics's valuation is estimated at $250.0M based on funding round data.
Can I buy SFA Therapeutics stock?
SFA Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SFA Therapeutics's last funding round?
SFA Therapeutics's most recent funding round was Series A on March 13, 2025.
Who are the main investors in SFA Therapeutics?
Key investors in SFA Therapeutics include Acequia Capital, Y Combinator, North South Ventures.
Will SFA Therapeutics IPO soon?
No public IPO plans have been announced for SFA Therapeutics.
How can I track SFA Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in SFA Therapeutics's shares on secondary markets.